Glycopeptide- and carbohydrate-based synthetic vaccines for the immunotherapy of cancer

On cancer cells, MUC-1 mucin displays distinct carbohydrate structures, such as Thomsen-Friedenreich (TF) and sialyl-Tn, the presence of which is attributed to reduced glycosylation activity. The core peptide is increasingly exposed and is recognized by the immune system. Vaccines based on both the...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 1996, Vol.1 (5), p.190-198
Main Authors: Koganty, R R, Reddish, MA, Longenecker, B M
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On cancer cells, MUC-1 mucin displays distinct carbohydrate structures, such as Thomsen-Friedenreich (TF) and sialyl-Tn, the presence of which is attributed to reduced glycosylation activity. The core peptide is increasingly exposed and is recognized by the immune system. Vaccines based on both the exposed core protein, which contains major histocompatibility complex unrestricted epitopes, and carbohydrate structures are targets for the immunotherapy of cancers of epithelial origin. A vaccine formulated using synthetic sialyl-Tn has proven to be highly target-specific in human trials, and the induction of high anti-STn antibody titers correlated with prolonged survival of breast cancer patients. Peptides and glycopeptides formulated as liposome-based vaccines have been effective in animal models.
ISSN:1359-6446
DOI:10.1016/1359-6446(96)10019-2